ODN?2216 is a TLR9 (toll-like receptor 9) ligand or agonist. ODN?2216 induces high amounts of IFN-α and IFN-β. ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4+ T cells[1][2][3][4].
ODN 2216 (6 μg/mL, 9 days) drives Th1 development of naive CD4 T cells[1].
ODN?2216 (2 μM, 15 h) significantly decreased apoptosis of thymic DC[2].
Apoptosis Analysis[2]
| Cell Line: | Thymic DC, pDC |
| Concentration: | 2 μM |
| Incubation Time: | 15 h |
| Result: | Significantly decreased apoptosis of thymic DC (23.1 ± 0.9%), and naturally induced apoptosis of thymic pDC was not decreased (72.8 ± 2.9%). |
ODN 2216 induces T-cell mediated antitumor immune response in murine vaccination models[3]